GTBP · GT Biopharma, Inc. · Financials
$6.47
-0.41 (-5.89%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$12.43M
Shares
1.80M
Volume · Sep 30
29.76K
Avg daily vol (16 sessions)
145.1K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2020
Net Income
-$28.35M
-115.4%
FY2025
Gross Margin
100%
+93.4pp
FY2015
Operating Margin
-33062.96%
-29135.1pp
FY2015
Diluted EPS
-$167.00
+3.7%
FY2025
Operating Cash Flow
-$12.91M
-0.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | — | — | — | $0 | $0 | — | $0 | $0 | $27K | $61K | $368K | $342K | $26K | $11K | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $57K | $226K | $94K | $48K | $65K | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $27K | $4000 | $142K | $248K | -$22K | -$54K | |
| — | — | — | — | — | — | — | — | — | — | — | 100% | 6.56% | 38.59% | 72.51% | -84.62% | -490.91% | |
| $3.48M | $3.47M | $5.8M | $6.47M | $8.81M | $9.59M | $485K | $1.67M | $9.07M | $1.07M | $975K | $1M | $0 | $0 | $0 | $17K | $179K | |
| $12.86M | $8.95M | $8.57M | $7.11M | $12.45M | $47.92M | $6.28M | $9.79M | $12.49M | $134.5M | $8.4M | $7.95M | $2.4M | $935K | $3.36M | $3.47M | $2.26M | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $22K | $2000 | $3000 | $23K | $31K | |
| — | — | — | $13.58M | $21.26M | $57.52M | — | $16.06M | $250.07M | $135.57M | $9.37M | $8.95M | $2.4M | $935K | $3.76M | $3.91M | $2.44M | |
| -$16.34M | -$12.42M | -$14.36M | -$13.58M | -$21.26M | -$57.52M | -$6.76M | $16.06M | -$250.07M | -$135.57M | -$9.37M | -$8.93M | -$2.4M | -$793K | -$3.51M | -$3.93M | -$2.5M | |
| — | — | — | — | — | — | — | — | — | — | — | -33062.96% | -3927.87% | -215.49% | -1027.49% | -15107.69% | -22700% | |
| — | $127K | — | $213K | $8000 | $718K | -$3M | -$2.13M | $9.12M | $8.6M | $6.56M | $17.04M | $5.15M | $1.2M | $1.65M | $556K | $513K | |
| $11.58M | -$15.93M | $1.2M | $5.98M | $373K | -$498K | -$21.53M | $22.59M | -$9.12M | -$8.6M | $19.14M | -$12.53M | -$21.11M | $229K | -$1.75M | $228K | -$498K | |
| -$14.83M | — | — | — | — | — | — | -$38.65M | -$259.19M | -$144.17M | $9.77M | -$21.46M | -$23.51M | -$564K | -$5.26M | -$3.7M | -$3M | |
| $0 | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$4.76M | -$28.35M | -$13.16M | -$7.6M | -$20.88M | -$58.01M | -$28.3M | -$38.65M | -$259.19M | -$144.17M | $9.77M | -$21.46M | -$23.49M | -$501K | -$5.17M | -$3.7M | -$3M | |
| — | — | — | — | — | — | — | — | — | — | — | -79485.19% | -38506.56% | -136.14% | -1511.99% | -14230.77% | -27227.27% | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | -$16K | -$63K | -$90K | $0 | — | |
| -$11.38M | -$34.45M | -$13.16M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | $108.50 | -$167.00 | -$173.50 | -$141.00 | -$491.50 | -$1,545.00 | — | — | -$65,790.00 | -$109,650.00 | $1,528,852.50 | -$114,240.00 | — | — | — | — | — |
| USD/shares | $108.50 | -$167.00 | -$173.50 | -$141.00 | -$491.50 | — | — | — | -$65,790.00 | -$109,650.00 | $1,528,852.50 | -$114,240.00 | — | — | — | — | — |
| shares | — | 220.53K | 75.9K | 53.91K | 42.49K | 37.54K | 5846.9627 | — | 3.9404 | 1.3152 | 6.389 | 187.8071 | 182.5783 | 44.44K | 29.15K | 15.77K | — |
| shares | — | 220.53K | 75.9K | 53.91K | 42.49K | 37.54K | 5846.9627 | 4511.9213 | 3.9404 | 1.3152 | 6.389 | 187.8071 | 182.5783 | 44.44K | 29.15K | 15.77K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.76×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.70×
Peer medians compare against the 225 similar-size Biotechnology companies (of 532 listed).